Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenesis of bronchiectasis.

Brian M Morrissey1

  • 1Division of Pulmonary/Critical Care Medicine, Department of Internal Medicine, School of Medicine, University of California-Davis, 4150 V Street, Suite 3400, Sacramento, CA 95817, USA. bnmorrissey@ucdavis.edu

Clinics in Chest Medicine
|May 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

α-Tocopherol Pharmacokinetics in Adults with Cystic Fibrosis: Benefits of Supplemental Vitamin C Administration.

Nutrients·2022
Same author

The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock.

Expert review of clinical pharmacology·2022
Same author

Quantitative assessment of cyanide in cystic fibrosis sputum and its oxidative catabolism by hypochlorous acid.

Free radical biology & medicine·2018
Same author

Safety and Clinical Utility of Flexible Bronchoscopic Cryoextraction in Patients With Non-neoplasm Tracheobronchial Obstruction: A Retrospective Chart Review.

Journal of bronchology & interventional pulmonology·2015
Same author

Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Journal of thoracic disease·2015
Same author

Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis.

Free radical biology & medicine·2014
Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026
Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026
Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026
Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026
Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026
See all related articles

Cystic fibrosis (CF) and non-CF bronchiectasis share common underlying mechanisms despite differing severity. Understanding these parallels offers new strategies to interrupt disease progression in both conditions.

Area of Science:

  • Pulmonology
  • Medical Science

Background:

  • Cystic fibrosis (CF) generally presents with a more severe clinical course compared to non-CF bronchiectasis.
  • Despite clinical differences, shared pathogenetic mechanisms in respiratory biology contribute to bronchiectasis development in both conditions.

Purpose of the Study:

  • To review and compare the clinical manifestations of bronchiectasis and CF.
  • To discuss the similarities and differences between CF and non-CF bronchiectasis.
  • To explore emerging parallels in the underlying mechanisms of these related respiratory diseases.

Main Methods:

  • Literature review of observed manifestations in bronchiectasis and CF.
  • Comparative analysis of disease characteristics.
  • Discussion of pathogenetic mechanisms.

Related Experiment Videos

Main Results:

  • Bronchiectasis and CF share commonalities in their underlying pathogenetic mechanisms.
  • Increasing understanding of bronchiectasis mechanisms reveals more parallels with CF.
  • Similarities exist in the anatomic deformations observed in both conditions.

Conclusions:

  • Despite differing severity, CF and non-CF bronchiectasis share common pathogenetic pathways.
  • Recognizing these parallels provides opportunities for novel therapeutic interventions.
  • Targeting shared mechanisms may offer a unified approach to halting disease progression.